Amicus Therapeutics, Inc. (NASDAQ:FOLD) went up by 6.83% from its latest closing price compared to the recent 1-year high of $16.13. The company’s stock price has collected 1.18% of gains in the last five trading sessions. Press Release reported on 09/03/20 that Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2020
Is It Worth Investing in Amicus Therapeutics, Inc. (NASDAQ :FOLD) Right Now?
Plus, the 36-month beta value for FOLD is at 1.19. Opinions of the stock are interesting as 9 analysts out of 11 who provided ratings for Amicus Therapeutics, Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $20.09, which is $5.73 above the current price. FOLD currently public float of 231.76M and currently shorts hold a 13.16% ratio of that float. Today, the average trading volume of FOLD was 2.44M shares.
FOLD’s Market Performance
FOLD stocks went up by 1.18% for the week, with a monthly drop of -6.20% and a quarterly performance of 23.61%, while its annual performance rate touched 40.51%. The volatility ratio for the week stands at 5.48% while the volatility levels for the past 30 days are set at 4.15% for Amicus Therapeutics, Inc.. The simple moving average for the period of the last 20 days is -3.07% for FOLD stocks with a simple moving average of 17.25% for the last 200 days.
Analysts’ Opinion of FOLD
Many brokerage firms have already submitted their reports for FOLD stocks, with BTIG Research repeating the rating for FOLD by listing it as a “Buy.” The predicted price for FOLD in the upcoming period, according to BTIG Research is $19 based on the research report published on June 17th of the current year 2020.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see FOLD reach a price target of $20, previously predicting the value of $19. The rating they have provided for FOLD stocks is “Overweight” according to the report published on February 4th, 2020.
H.C. Wainwright gave a rating of “Buy” to FOLD, setting the target price at $20 in the report published on November 12th of the previous year.
FOLD Trading at -6.55% from the 50-Day Moving Average
After a stumble in the market that brought FOLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.63% of loss for the given period.
Volatility was left at 4.15%, however, over the last 30 days, the volatility rate increased by 5.48%, as shares sank -4.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.45% lower at present.
During the last 5 trading sessions, FOLD rose by +1.18%, which changed the moving average for the period of 200-days by +32.66% in comparison to the 20-day moving average, which settled at $14.17. In addition, Amicus Therapeutics, Inc. saw 41.38% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at FOLD starting from WHITMAN BURKE W, who bought 1,500 shares at the price of $14.62 back on Sep 01. After this action, WHITMAN BURKE W now owns 33,967 shares of Amicus Therapeutics, Inc., valued at $21,930 using the latest closing price.
Crowley John F, the Chairman & CEO of Amicus Therapeutics, Inc., sold 29,900 shares at $14.18 during a trade that took place back on Sep 01, which means that Crowley John F is holding 850,813 shares at $423,850 based on the most recent closing price.
Stock Fundamentals for FOLD
Current profitability levels for the company are sitting at:
- -165.03 for the present operating margin
- +85.33 for the gross margin
The net margin for Amicus Therapeutics, Inc. stands at -195.56. The total capital return value is set at -44.51, while invested capital returns managed to touch -53.03. Equity return is now at value -65.50, with -36.90 for asset returns.
Based on Amicus Therapeutics, Inc. (FOLD), the company’s capital structure generated 44.13 points at debt to equity in total, while total debt to capital is 30.62. Total debt to assets is 24.73, with long-term debt to equity ratio resting at -15.94. Finally, the long-term debt to capital ratio is 42.62.
When we switch over and look at the enterprise to sales, we see a ratio of 11.52, with the company’s debt to enterprise value settled at 0.10. The receivables turnover for the company is 6.60 and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.04.